» Articles » PMID: 28427510

Central Nervous System Gliomas

Overview
Specialty Hematology
Date 2017 Apr 22
PMID 28427510
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence-based practical guidelines on diagnosis, prognosis, and treatment on the most frequent adult brain tumours are delineated. In Europe, 27,000 new cases of malignant glial tumours and 1000 new cases of malignant ependymal tumours are diagnosed every year. The most common glial tumours are glioblastoma multiforme and anaplastic glioma, comprising more than 50% and 10%, respectively, of the total gliomas. Prognosis of gliomas is generally poor. Environmental and genetic factors have been correlated with an increased risk of developing brain tumours. Surgical resection represents the first treatment option for all histotypes. Role and timing of radiotherapy and chemotherapy as well as treatment for recurrent/progressive disease should be based on age, performance status, histopathological diagnosis, molecular markers, and previous therapy. Impaired neurocognitive and neuropsychological function is common in long-term survivors, regardless of the histology and grade of the tumour and should be taken into account in treatment planning.

Citing Articles

Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy.

Ohba S, Teranishi T, Matsumura K, Kumon M, Kojima D, Fujiwara E Sci Rep. 2025; 15(1):1750.

PMID: 39799218 PMC: 11724988. DOI: 10.1038/s41598-025-85339-x.


The Activity of 1,8-Dihydroanthraquinone Derivatives in Nervous System Cancers.

Okon E, Kukula-Koch W, Jarzab A, Gawel-Beben K, Bator E, Michalak-Tomczyk M Molecules. 2025; 29(24.

PMID: 39770078 PMC: 11677425. DOI: 10.3390/molecules29245989.


Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.

Dhiman A, Rana D, Benival D, Garkhal K Ther Deliv. 2024; 16(1):87-115.

PMID: 39445563 PMC: 11703381. DOI: 10.1080/20415990.2024.2415281.


CSF3R as a potential prognostic biomarker and immunotherapy target in glioma.

Huang M, Zhang L, Wu Y, Zhou X, Wang Y, Zhang J Cent Eur J Immunol. 2024; 49(2):155-168.

PMID: 39381559 PMC: 11457564. DOI: 10.5114/ceji.2024.140651.


ELF4 was a prognostic biomarker and related to immune infiltrates in glioma.

Zhuang Z, Zhang C, Tan Y, Zhang J, Zhong C J Cancer. 2024; 15(15):5101-5117.

PMID: 39132148 PMC: 11310870. DOI: 10.7150/jca.96886.